Final published version, 1.04 MB, PDF document
Available under license: CC BY: Creative Commons Attribution 4.0 International License
Final published version
Licence: CC BY: Creative Commons Attribution 4.0 International License
Research output: Contribution to Journal/Magazine › Review article › peer-review
Research output: Contribution to Journal/Magazine › Review article › peer-review
}
TY - JOUR
T1 - Antiviral Nanomedicine‑Based Approaches against Epstein‑Barr Virus Infection
AU - Abdelmonem, Mohamed
AU - Che Abdullah, Che Azurahanim
AU - Bastawecy, Iman M.
AU - Raof, Amal M. A.
AU - Afify, Ahmed F.
AU - El Naggar, Rania
AU - Rohaim, Mohammed
AU - Munir, Muhammad
PY - 2024/2/17
Y1 - 2024/2/17
N2 - Purpose of ReviewThe Epstein-Barr virus (EBV) is a common virus around the globe with approximately 98% of adults testing positive against EBV. However, EBV infection typically begins early in the childhood. Owing to the ability to infect various body organ, EBV is linked to a broad spectrum of symptoms, diseases, and inflammatory conditions. Moreover, since EBV exists in both latent and replicating forms in most healthy individuals, any disruption in the balance between the virus and its host can lead to the development of different diseases, including autoimmune disorders and cancer. Given these circumstances, we draw attention to the crucial need for developing prophylactic measures and treatments for EBV and its associated diseases.Recent FindingsWe propose leveraging the advantages of nanomedicine, such as ferritin and iron oxide nanoparticles, for the creation of EBV vaccines. These advancements can also be applied to developing drugs to treat EBV-associated diseases, such as cancer, autoimmune disorders, and cytokine storm syndrome.SummaryWe emphasize the urgency of having accessible EBV vaccines, as well as effective treatments for EBV-related diseases, especially when early diagnosis is involved. This approach, which includes comprehensive cytokine profiling for patients, can significantly enhance the effectiveness of treatment programs.
AB - Purpose of ReviewThe Epstein-Barr virus (EBV) is a common virus around the globe with approximately 98% of adults testing positive against EBV. However, EBV infection typically begins early in the childhood. Owing to the ability to infect various body organ, EBV is linked to a broad spectrum of symptoms, diseases, and inflammatory conditions. Moreover, since EBV exists in both latent and replicating forms in most healthy individuals, any disruption in the balance between the virus and its host can lead to the development of different diseases, including autoimmune disorders and cancer. Given these circumstances, we draw attention to the crucial need for developing prophylactic measures and treatments for EBV and its associated diseases.Recent FindingsWe propose leveraging the advantages of nanomedicine, such as ferritin and iron oxide nanoparticles, for the creation of EBV vaccines. These advancements can also be applied to developing drugs to treat EBV-associated diseases, such as cancer, autoimmune disorders, and cytokine storm syndrome.SummaryWe emphasize the urgency of having accessible EBV vaccines, as well as effective treatments for EBV-related diseases, especially when early diagnosis is involved. This approach, which includes comprehensive cytokine profiling for patients, can significantly enhance the effectiveness of treatment programs.
KW - Drugs
KW - Epstein-Barr virus
KW - Latent
KW - Nanomedicine
KW - Treatment
KW - Vaccines
U2 - 10.1007/s40506-024-00271-4
DO - 10.1007/s40506-024-00271-4
M3 - Review article
VL - 16
SP - 58
EP - 71
JO - Current Treatment Options in Infectious Diseases
JF - Current Treatment Options in Infectious Diseases
SN - 1534-6250
IS - 2
ER -